Ryan H. Huston

Ryan H. Huston

Auto-generated profile, based on publicly available information

Ryan H. Huston

Department of Microbiology, The Ohio State University, Columbus, OH 43210, USA; Department of Pathology, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2022 in npj Vaccines
Verified
Journal Article
Open access
PDF file
GVGreta Volpedo
Greta Volpedo
TPThalia Pacheco-Fernandez
Thalia Pacheco-Fernandez
EHErin A. Holcomb
Erin A. Holcomb
WZWen-Wei Zhang
Wen-Wei Zhang
PLPatrick Lypaczewski
Patrick Lypaczewski
Abhay SatoskarAbhay Satoskar
Abhay Satoskar
Leishmaniasis is a neglected protozoan disease affecting over 12 million people globally with no approved vaccines for human use. New World cutaneous leishmaniasis (CL) caused by L. mexicana is characterized by the development of chronic non-healing skin lesions. Using the CRISPR/Cas9 technique, we have generated live attenuated centrin knockout L. mexicana (LmexCen−/−) parasites. Centrin is a cytoskeletal protein important for cellular division in eukaryotes and, in Leishmania, is required only for intracellular amastigote replication. We have investigated the safety and immunogenicity characteristics of LmexCen−/− parasites by evaluating their survival and the cytokine production in bone-marrow-derived macrophages (BMDMs) and dendritic cells (BMDCs) in vitro. Our data shows that LmexCen−/− amastigotes present a growth defect, which results in significantly lower parasitic burdens and increased protective cytokine production in infected BMDMs and BMDCs, compared to the wild type (WT) parasites. We have also determined the safety and efficacy of LmexCen−/− in vivo using experimental murine models of L. mexicana. We demonstrate that LmexCen−/− parasites are safe and do not cause lesions in susceptible mouse models. Immunization with LmexCen−/− is also efficacious against challenge with WT L. mexicana parasites in genetically different BALB/c and C57BL/6 mouse models. Vaccinated mice did not develop cutaneous lesions, displayed protective immunity, and showed significantly lower parasitic burdens at the infection site and draining lymph nodes compared to the control group. Overall, we demonstrate that LmexCen−/− parasites are safe and efficacious against New World cutaneous leishmaniasis in pre-clinical models.

1 July 2023 in Research and Reports in Tropical Medicine
Verified
Journal Article
Open access
PDF file
TPThalia Pacheco-Fernandez
Thalia Pacheco-Fernandez
HMHannah Markle
Hannah Markle
CVChaitenya Verma
Chaitenya Verma
RHRyan Huston
Ryan Huston
SGSreenivas Gannavaram
Sreenivas Gannavaram
Abhay SatoskarAbhay Satoskar
Abhay Satoskar
Leishmaniasis is a neglected tropical disease endemic primarily to low- and middle-income countries, for which there has been inadequate development of affordable, safe, and efficacious therapies. Clinical manifestations of leishmaniasis range from self-healing skin lesions to lethal visceral infection with chances of relapse. Although treatments are available, secondary effects limit their use outside the clinic and negatively impact the quality of life of patients in endemic areas. Other non-medicinal treatments, such as thermotherapies, are limited to use in patients with cutaneous leishmaniasis but not with visceral infection. Recent studies shed light to mechanisms through which Leishmania can persist by hiding in cellular safe havens, even after chemotherapies. This review focuses on exploring the cellular niches that Leishmania parasites may be leveraging to persist within the host. Also, the cellular, metabolic, and molecular implications of Leishmania infection and how those could be targeted for therapeutic purposes are discussed. Other therapies, such as those developed against cancer or for manipulation of the ferroptosis pathway, are proposed as possible treatments against leishmaniasis due to their mechanisms of action. In particular, treatments that target hematopoietic stem cells and monocytes, which have recently been found to be necessary components to sustain the infection and provide a safe niche for the parasites are discussed in this review as potential field-deployable treatments against leishmaniasis.

9 January 2025 in Expert Reviews in Molecular Medicine
Verified
Journal Article
Open access
PDF file
OBOlivia Battistoni
Olivia Battistoni
RHRyan H. Huston
Ryan H. Huston
Chaitenya VermaChaitenya Verma
Chaitenya Verma
TPThalia Pacheco-Fernandez
Thalia Pacheco-Fernandez
SASara Abul-Khoudoud
Sara Abul-Khoudoud
Abhay SatoskarAbhay Satoskar
Abhay Satoskar
Background: Leishmaniasis, Chagas disease (CD), and Human African Trypanosomiasis (HAT) are neglected tropical diseases in humans caused by intracellular parasites from the class Kinetoplastida. Leishmaniasis is one infectious disease that exhibits sex-bias not explained solely by behavioral or cultural differences. However, HAT and CD have less well documented and understood sex-related differences, either due to a lack of differences or insufficient research and reporting. Methods: This paper reviews the rate of disease and disease severity among male and females infected with CD, HAT, and leishmaniasis. We further review the specific immune response to each pathogen and potential sex-based mechanisms which could impact immune responses and disease outcomes. Results: These mechanisms include sex hormone modulation of the immune response, sex-related genetic differences, and socio-cultural factors impacting risky behaviors in men and women. The mechanistic differences in immune response among sexes and pathogens provide important insights and identification of areas for further research. Conclusions: This information can aid in future development of inclusive, targeted, safe, and effective treatments and control measures for these neglected diseases and other infectious diseases.

30 October 2025 in Phytomedicine
Verified
Journal Article
Open access
MDM. Junaid Dar
M. Junaid Dar
SGSreenivas Gannavaram
Sreenivas Gannavaram
RHRyan H. Huston
Ryan H. Huston
CTCharles Thomas
Charles Thomas
HNHira L Nakhasi
Hira L Nakhasi
Abhay SatoskarAbhay Satoskar
Abhay Satoskar
Leishmaniasis is a neglected tropical disease caused by protozoan parasites of the genus Leishmania and remains a significant global health burden due to limited therapeutic options and emerging drug resistance, necessitating the search for alternative therapeutic agents. Our earlier studies have shown that Pentalinonsterol (Pen), isolated from Pentalinon andrieuxii plant, showed promising antileishmanial activities. However, the effects of Pen on the transcriptomic profile and nuclear factor erythroid 2-related factor 2 (Nrf-2) related alterations in host cells remain unclear. The present study examines the impact of Pen on the transcriptomic profiles of human macrophages infected with Leishmania major, with a particular focus on its modulation of Nrf-2 pathway. Bulk RNA-seq analysis revealed 1245 differentially expressed genes (DEGs), including 678 upregulated and 567 downregulated genes, using a significance threshold of log2 fold change ≥ 2 and a false discovery rate ≤ 0.05. We found significant modulation of key cytokines, chemokines, and immune effector genes, including downregulation of IL-10, CXCL2, and CXCR3, and upregulation of TXN, GSR, SOD1, and CXCL8 indicating a selectively regulated inflammatory response. Pathway enrichment analysis demonstrated that Pen modified transcriptional profiles related to oxidative stress responses, validated by RT-PCR and confirmed by increased nuclear Nrf-2 translocation through biochemical and immunofluorescence assays. These findings highlight Pen's potential as a dual action therapeutic, selectively modulating immune responses in favor of pathogen control while activating Nrf-2 driven antioxidant defenses to counteract oxidative stress. This integrated activity supports Pen's further advancement as a novel host directed therapeutic for leishmaniasis and other Nrf-2 associated inflammatory conditions.